๋ถํ๋ ๋ ธ๋ฅดํ
๋ถํ๋ ๋ ธ๋ฅดํ์ ์์ํ์์ ๋๋ฆฌ ์ฌ์ฉ๋๋ **์คํผ์ค์ด๋ ๋ถ๋ถ ์์ฉ์ **์ ๋๋ค. ์ฃผ๋ก ์๋๋ฌผ์ ๊ฒฝ๋ ๋ฐ ์ค๋ฑ๋ ๊ธ์ฑ ํต์ฆ ๊ด๋ฆฌ์ ์ฌ์ฉ๋๋ฉฐ, ์ํ-2 ์์ฉ์ ๋ฐ ํด๋ฆฌ์ฑ ๋ง์ทจ์ ์ ํจ๊ป ๋จ๊ธฐ ๋ณด์ ์ฉ '์นตํ ์ผ' ์๋ฒ์ ์์ฃผ ํฌํจ๋ฉ๋๋ค. * **์์์ ํน์ง**: ๋ถํ๋ ๋ ธ๋ฅดํ์ ํ์ค ์ฉ๋์์ "์ฒ์ฅ ํจ๊ณผ(ceiling effect)"๋ฅผ ๋ํ๋ ๋๋ค. ์ฆ, ํน์ ์ง์ ์ด์์ผ๋ก ์ฉ๋์ ๋๋ ค๋ ์ถ๊ฐ์ ์ธ ์งํต ํจ๊ณผ๋ฅผ ์ป์ง ๋ชปํ ์ ์์ผ๋ฉฐ ์ด๋ก ์ ์ผ๋ก ์งํต ํจ๋ฅ์ด ๊ฐ์ํ ์ ์์ต๋๋ค. * **๊ณ ์์ด์์์ ์ฅ์ **: ๊ณ ์์ด์ ๊ตฌ๊ฐ pH๋ ๋น๊ต์ ์์นผ๋ฆฌ์ฑ์ด์ด์ ๋ถํ๋ ๋ ธ๋ฅดํ์ด ๋์ ์ง์ฉ์ฑ์ ๋ ๊ฒ ๋๋ฉฐ, ์ด๋ ์ฐ์ํ **๊ตฌ๊ฐ ์ ๋ง(OTM) / ๋ณผ ์ ๋ง ํก์**๋ฅผ ๊ฐ๋ฅํ๊ฒ ํฉ๋๋ค. ๊ณ ์์ด์์ ๋ณผ ์ ๋ง ํฌ์ฌ๋ ๊ทผ์ก ์ฃผ์ฌ์ ๊ฑฐ์ ๋์ผํ ์์ฒด์ด์ฉ๋ฅ ์ ๊ฐ์ง๋ฏ๋ก ๊ฐ์ ๋ด ์์ ํ ํต์ฆ ๊ด๋ฆฌ์ ๋งค์ฐ ์ค์ฉ์ ์ธ ํฌ์ฌ ๊ฒฝ๋ก์ ๋๋ค. * **์ง์ ์๊ฐ**: ์์ ๋ฎค-์์ฉ์ (ํํ๋ ๋๋ ๋ฉํ๋ ๋ฑ)์ ๋นํด ์์ฉ ๋ฐํ ์๊ฐ์ ๊ธธ์ง๋ง, ์งํต ์ง์ ์๊ฐ์ ํจ์ฌ ๊น๋๋ค(์ผ๋ฐ์ ์ผ๋ก 6~8์๊ฐ, ์ต๋ 12์๊ฐ). * **๊ท์ **: ์ด ์ฝ๋ฌผ์ ๋ง์ฝ๋ฅ(ํฅ์ ์ ์ฑ์์ฝํ)๋ก ๋ถ๋ฅ๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Buprenorphine exerts its analgesic effects by acting as a **partial agonist at the mu (ฮผ) opioid receptor** and an **antagonist at the kappa (ฮบ) opioid receptor** in the central nervous system. * **High Affinity, Slow Dissociation**: It binds to the ฮผ-receptor with an affinity approximately 30 times greater than morphine. This tight binding โ prolonged duration of action. * **Receptor Competition**: Because of its high affinity, it can displace pure ฮผ-agonists from the receptor, potentially antagonizing their analgesic effects while reversing their sedative and respiratory depressant effects. * **Naloxone Resistance**: Its slow dissociation from the receptor makes it notoriously difficult to fully reverse with standard doses of the opioid antagonist **naloxone**; high doses of naloxone or the use of doxapram may be required in cases of severe respiratory depression.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Analgesia ยท 0.005-0.02 mg/kg IM, IV or SC q6-12h ยท IM, IV, SC ยท q6-12h
- Analgesia ยท 2-4 micrograms/kg/hour ยท IV ยท continuous infusion
- Analgesia ยท 0.005-0.03 mg/kg IV, IM, SC, epidural ยท IV, IM, SC, epidural
- Analgesia ยท 0.006-0.02 mg/kg IV, IM, SQ ยท IV, IM, SQ ยท 6-12 hours ยท Relatively effective analgesic, but may be difficult to reverse with naloxone if untoward effects are seen.
- Analgesia ยท 0.02 mg/kg ยท IV, IM, SC ยท q6h ยท SC route is listed in historical dosing but text notes it is not recommended due to potentially lower efficacy compared to IM/IV.
- Analgesia ยท 0.01-0.05 mg/kg SC or IM 2-3 times daily ยท SC, IM ยท 2-3 times daily
- Analgesia ยท 0.01-0.03 mg/kg IM, IV, Buccal ยท IM, IV, Buccal ยท up to 6 hours ยท Buccal use is well accepted by cats.
- Analgesia ยท 0.01-0.03 mg/kg PO transmucosally (squirted directly into the mouth) q8h ยท PO transmucosal ยท q8h
- Analgesia ยท 0.01-0.03 mg/kg IM, IV, SC q6-8h; 0.01-0.03 mg/kg PO q6-12h ยท IM, IV, SC, PO ยท q6-12h
- Analgesia ยท 1-3 micrograms/kg/hour ยท IV ยท continuous infusion
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity to buprenorphine
์ด์๋ฐ์
- Respiratory depression (rare but significant)
- Sedation
- Urine retention or difficulty voiding (particularly with high IV or epidural doses)
- Excitement (horses)
- Diminished gut sounds (horses)
- Vomiting (rare in cats)
์ฝ๋ฌผ ์ํธ์์ฉ
- Local Anesthetics (mepivacaine, bupivacaine) ยท May be potentiated by concomitant use of buprenorphine
- Anticonvulsants (phenobarbital, phenytoin) ยท May decrease plasma buprenorphine levels
- Benzodiazepines ยท Case reports of humans developing respiratory/cardiovascular/CNS depression; use with caution
- CNS Depressants (anesthetics, antihistamines, phenothiazines, barbiturates, alcohol) ยท May cause increased CNS or respiratory depression when used with buprenorphine
- Erythromycin ยท Can increase plasma buprenorphine levels
- Fentanyl (and other pure opiate agonists) ยท Buprenorphine may potentially antagonize some analgesic effects, but may also reverse some sedative and respiratory depressant effects
- Halothane ยท Potentially can increase buprenorphine effects
- Azole Antifungals (ketoconazole, itraconazole, fluconazole) ยท Can increase plasma buprenorphine levels
- Monoamine Oxidase Inhibitors (selegiline, amitraz) ยท Possible additive effects or increased CNS depression
- Naloxone ยท May reduce analgesia associated with high dose buprenorphine
- Pancuronium ยท If used with buprenorphine may cause increased conjunctival changes
- Rifampin ยท Potentially decrease plasma buprenorphine concentrations
๋ชจ๋ํฐ๋ง
- Analgesic efficacy
- Respiratory status
- Cardiac status
๊ณผ์ฉ๋
Buprenorphine has a very high index of safety (ratio of lethal dose to effective dose is at least 1000:1 in rodents). Life-threatening acute overdoses are rare in veterinary medicine, but clinical signs are common. * **Clinical Signs (Dogs)**: Vocalization, ataxia, hypersalivation, hypothermia, and lethargy. * **Treatment**: Supportive care. In cases of acute overdose causing severe respiratory or cardiac effects, **naloxone** and **doxapram** are suggested. > **Note**: Due to buprenorphine's extremely high affinity for the mu-receptor, standard doses of naloxone may be ineffective; very high doses of naloxone may be required to reverse respiratory depression.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.